Inhibition of flavivirus replication and assembly

抑制黄病毒复制和组装

• 批准号: 7672018
• 负责人: Richard J. Kuhn
• 金额: $ 24.75万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-24 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7672018
• 关键词: Animal Model; Antiviral Agents; Basic Science; Binding; Categories; Cell Culture Techniques; Collaborations; Data; Dengue Virus; Development; E protein; Evaluation; Flavivirus; Genome; Glucosides; In Vitro; Infection; Intervention; Life Cycle Stages; Medical; Molecular; Molecular Conformation; National Institute of Allergy and Infectious Disease; Pharmaceutical Chemistry; Pharmaceutical Preparations; Process; Proteins; Public Health; RBBP9 gene; RNA Viruses; Reagent; Replicon; Site; Structural Protein; Symptoms; United States; Viral; Virion; Virus; base; biodefense; env Gene Products; genetic selection; in vivo; in vivo Model; inhibitor/antagonist; insight; member; molecular assembly/self assembly; multidisciplinary; particle; pathogen; pre-clinical; protein protein interaction; small molecule

This project will use a multidisciplinary team of molecular, structural, and computational biologists together with medicinal chemists to develop and evaluate compounds that have inhibitory activity against the flavivirus genus of plus strand RNA viruses. These compounds will be used to probe the function of their target proteins in the life cycle of the virus. This project builds on existing collaborations and extends previous observations by the Purdue group. The flaviviruses contain members of MAID Priority Pathogens that are found in all three categories A-C. The focus will be primarily on dengue virus, a category A pathogen, because of both its medical importance and the substantial structural data and reagents that we and others have compiled over the last several years. We will combine both foundational basic research, together with a translational component that involves in vitro and in vivo compound evaluation to identify small molecules suitable for pre-clinical antiviral development. The approaches used to identify such compounds will also yield insight into the assembly and replication of flaviviruses. We will determine the conformational states of the flavivirus structural proteins as they progress in the immature virion to the mature state, and evaluate the ability of compounds to interfere with these transitions and the process of viral entry. We will evaluate the dynamic states of the flavivirus particle, the structural transitions that occur during maturation and entry, and the binding of small molecule inhibitors to the envelope proteins. Two sets of inhibitory molecules have been developed based on predicted binding to 1) an E protein n-octyl-b-Dglucoside (BOG) binding pocket; and 2) sites on E that are involved in protein - protein interactions. These two sets serve as starting reagents in compound evaluation and further development. We will also identify compounds that inhibit flavivirus genome replication, identify their mechanism of inhibition, and evaluate their efficacy in an animal model. A high throughput flavivirus replicon screen was used to identify small molecule inhibitors of replication. Targets of these inhibitors will be identified by genetic selection, initial hits will be expanded by successive rounds of medicinal chemistry, and the compounds will be evaluated both in vitro using cell culture models and in vivo using small animal models.

这个项目将使用分子，结构和计算生物学家的多学科团队一起 与药物化学家合作，开发和评估具有抑制活性的化合物， 正链RNA病毒的黄病毒属。这些化合物将被用来探测它们的功能。 病毒生命周期中的靶蛋白。该项目建立在现有的合作基础上， Purdue集团之前的观察结果。黄病毒含有MAID优先病原体成员 在A-C三个类别中都有。重点将主要放在登革热病毒上， 病原体，因为它的医学重要性和大量的结构数据和试剂，我们 和其他人在过去几年里编写的。我们将联合收割机和基础性的基础研究结合起来， 与涉及体外和体内化合物评价的翻译组分一起， 适合于临床前抗病毒开发的小分子。用于识别此类行为的方法 化合物也将使我们深入了解黄病毒的装配和复制。康贝特人将以 黄病毒结构蛋白的构象状态，因为它们在未成熟的病毒体中进展到 成熟状态，并评估化合物干扰这些转变和过程的能力。 病毒入侵我们将评估黄病毒颗粒的动态状态，即发生的结构转变 在成熟和进入期间，以及小分子抑制剂与包膜蛋白的结合。两套 基于预测的与1）E蛋白正辛基-β-D葡糖苷的结合，已经开发了10种抑制分子 (BOG)结合口袋;和2）E上参与蛋白质-蛋白质相互作用的位点。这些 两组用作化合物评价和进一步开发的起始试剂。我们还将确定 本发明涉及抑制黄病毒基因组复制的化合物，鉴定它们的抑制机制，并评价它们的 在动物模型中的功效。高通量黄病毒复制子筛选用于鉴定小分子 复制抑制剂。这些抑制剂的靶点将通过遗传选择来鉴定，初始命中将通过遗传选择来确定。 通过连续几轮的药物化学扩展，化合物将在体外和体外进行评估。 使用细胞培养模型和体内使用小动物模型。